Research-Grade Peptides. Verified to Standard.
USA manufactured.
GMP-compliant. HPLC and mass spectrometry tested. Every batch ships with a Certificate of Analysis.
The Standard Exists for a Reason.
The peptide supply market is inconsistent. Purity claims without documentation. Batch-to-batch variability with no accountability. Manufacturing origins that are unverifiable.
BioRhex was built to operate differently.
Every compound is synthesized in a GMP-compliant, US-based facility. Every batch is tested by independent third-party laboratories using HPLC and mass spectrometry verification, with sterility testing conducted to research-grade standards.
Every order ships with a Certificate of Analysis — not as a marketing feature, but as a baseline requirement.
≥99% purity is not a claim. It is a documented, verifiable threshold we hold every batch to before it ships.
This is not a higher bar than other suppliers. This is the bar that should have existed from the start.
Our Compounds
CJC (no DAC) + Ipamorelin (10mg)
CJC (no DAC) + Ipamorelin is a research-grade blend combining two complementary GH axis peptides. CJC-1295 without Drug Affinity Complex is a GHRH analogue engaging the hypothalamic-pituitary axis at the GHRH receptor level. Ipamorelin is a selective GHSR-1a agonist engaging the ghrelin receptor pathway. In research settings, this combination is studied for its dual-mechanism GH axis engagement and associated downstream signaling.
BioRhex supplies CJC (no DAC) + Ipamorelin as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.
IGF-1 LR3 (1mg)
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), comprising the full 44-amino-acid GHRH sequence modified with a trans-3-hexenoic acid conjugation to improve metabolic stability. In research settings, Tesamorelin is studied for its interactions with pituitary GHRH receptors, growth hormone secretion dynamics, and downstream IGF-1 axis signaling.
BioRhex supplies Tesamorelin as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.
Ipamorelin (5mg)
Ipamorelin is a synthetic pentapeptide and selective growth hormone secretagogue receptor (GHSR-1a) agonist. In research settings, Ipamorelin is studied for its receptor selectivity profile, pituitary somatotroph GH secretion dynamics, and pharmacological comparison against other GHS compounds.
BioRhex supplies Ipamorelin as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.
Sermorelin (5mg)
Sermorelin is a synthetic peptide analogue representing the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH 1-29-NH₂). In research settings, Sermorelin is studied for its binding interactions with pituitary GHRH receptors, somatotroph cell biology, and GH secretion dynamics relative to full-length GHRH.
BioRhex supplies Sermorelin as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.
Tesamorelin (10mg)
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), comprising the full 44-amino-acid GHRH sequence modified with a trans-3-hexenoic acid conjugation to improve metabolic stability. In research settings, Tesamorelin is studied for its interactions with pituitary GHRH receptors, growth hormone secretion dynamics, and downstream IGF-1 axis signaling.
BioRhex supplies Tesamorelin as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.
AOD9604 (5mg)
AOD9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (hGH 177-191), with an additional tyrosine residue at the N-terminus. In research settings, AOD9604 is examined for its interactions with adipocyte signaling pathways and lipolytic mechanisms — studied independently of the growth-promoting effects associated with full-length GH.
BioRhex supplies AOD9604 as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.
MOTS-C (10mg)
MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within mitochondrial DNA, specifically within the 12S ribosomal RNA gene. In research settings, MOTS-C is studied for its role in AMPK pathway activation, insulin signaling interactions, and mitochondrial-nuclear communication dynamics.
BioRhex supplies MOTS-C as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.
Retatrutide (20mg)
Retatrutide is a synthetic peptide designed as a triple agonist of the GIP receptor (GIPR), GLP-1 receptor (GLP-1R), and glucagon receptor (GCGR). In research settings, Retatrutide is studied for its simultaneous activation of three metabolic receptor pathways and the resulting complex signaling interactions across pancreatic, hepatic, hypothalamic, and adipose tissue models.
BioRhex supplies Retatrutide as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.
Semaglutide (20mg)
Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), modified with a C18 fatty acid chain conjugation to enable albumin binding and extend half-life. In research settings, Semaglutide is studied for its interactions with GLP-1 receptors in pancreatic, hypothalamic, hepatic, and peripheral tissue models.
BioRhex supplies Semaglutide as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.
SLU-PP-332
SLU-PP-332 is a synthetic small molecule pan-agonist of estrogen-related receptors (ERRα, ERRβ, ERRγ) — nuclear receptors that regulate mitochondrial biogenesis, oxidative metabolism, and energy expenditure gene networks. In research settings, SLU-PP-332 is studied for its interactions with ERR-mediated transcriptional pathways and downstream metabolic signaling.
BioRhex supplies SLU-PP-332 as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.
Selank (10mg)
Selank is a synthetic heptapeptide derived from the immunomodulatory peptide Tuftsin (Thr-Lys-Pro-Arg), with an appended Gly-Glu-Thr sequence to improve metabolic stability. In research settings, Selank is examined for its interactions with GABA-A receptor systems, serotonin pathway modulation, and enkephalin degradation inhibition in central nervous system models.
BioRhex supplies Selank as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.
Semax (10mg)
Semax is a synthetic heptapeptide analogue of the ACTH(4-7) fragment, modified with a C-terminal Pro-Gly-Pro extension to enhance metabolic stability and CNS activity. In research settings, Semax is studied for its interactions with neurotrophin signaling pathways, BDNF expression modulation, and neuroprotective mechanisms in central nervous system models.
BioRhex supplies Semax as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.
BPC-157
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a partial sequence of a naturally occurring gastric protection protein found in human gastric juice. In research settings, BPC-157 is examined for its interactions with angiogenic pathways, cellular repair signaling, and inflammatory mediator modulation in laboratory models.
BioRhex supplies BPC-157 (5mg) as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.
BPC-157 + TB-500
BPC-157 + TB-500 is a research-grade blend combining two complementary tissue signaling peptides: BPC-157, a 15-amino-acid gastric-derived peptide, and TB-500, the active fragment of Thymosin Beta-4. In research settings, this combination is studied for its dual-pathway interactions across angiogenesis signaling, actin biology, cellular migration dynamics, and tissue repair mechanisms.
BioRhex supplies BPC-157 + TB-500 (20mg) as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.
GHK-Cu (50mg)
GHK-Cu (Glycine-Histidine-Lysine Copper) is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. In research settings, GHK-Cu is studied for its interactions with collagen synthesis pathways, fibroblast activity, angiogenesis signaling, and extracellular matrix remodeling in tissue biology models.
BioRhex supplies GHK-Cu as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.
KLOW (80mg)
KLOW is BioRhex's proprietary recovery research blend combining four complementary peptides in a single compound: BPC-157 (gastric-derived pentadecapeptide), TB-500 (Thymosin Beta-4 active fragment), KPV (alpha-MSH C-terminal tripeptide), and GHK-Cu (copper-binding tripeptide). In research settings, KLOW is studied as a multi-pathway approach to tissue repair signaling, inflammatory modulation, and cellular recovery mechanism research.
BioRhex supplies KLOW as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.
TB-500
TB-500 is a synthetic peptide fragment corresponding to the actin-binding active region of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid protein involved in actin cytoskeletal regulation and cellular biology. In research settings, TB-500 is studied for its interactions with G-actin sequestration, endothelial and smooth muscle cell migration signaling, and angiogenesis pathway dynamics.
BioRhex supplies TB-500 (10mg) as a research compound manufactured in a GMP-compliant US facility, tested to ≥99% purity via HPLC and mass spectrometry, and supplied strictly for controlled laboratory research — not for human or animal use.
Research Compounds by Category
Every compound is manufactured in the USA, GMP-compliant, and COA-verified at ≥99% purity.
Cellular Health & Longevity Research
Compounds studied for mitochondrial function, cellular signaling, and longevity pathway modulation
Growth Signaling Research
Peptides examined for GH secretagogue activity, IGF-1 axis interactions, and growth signaling modulation.
Metabolic Pathway Research
Compounds investigated for metabolic regulation, GLP-1 receptor activity, and body composition pathway research.
Neurocognitive Research
Peptides studied for neuropeptide modulation, anxiolytic pathways, and cognitive signaling research.
Recovery & Tissue Research
Compounds examined for tissue repair signaling, angiogenesis pathways, and cellular recovery mechanisms.
What Every BioRhex Compound Goes Through
No compound ships without meeting every requirement below.
USA Manufacturing
Synthesized in a domestic, GMP-compliant facility. No offshore sourcing. No unverifiable supply chain.
GMP-Compliant Production
Every compound is produced under Good Manufacturing Practice standards, ensuring consistency across every batch.
HPLC Purity Verification
High-performance liquid chromatography testing confirms compound identity and purity against established reference standards.
Mass Spectrometry Confirmation
Mass spectrometry analysis verifies molecular weight and compound identity, providing a second independent layer of purity confirmation.
Sterility Testing
Each batch undergoes sterility testing to research-grade standards before release.
≥99% Purity Threshold
BioRhex maintains a minimum purity threshold of ≥99% across all compounds. Batches that do not meet this standard are not released.
High-Demand Research Compounds
- In stock
- COA-verified
- ≥99% purity.
- USA manufactured.
- In stock
- COA-verified
- ≥99% purity.
- USA manufactured.
- COA-verified
- In stock
- ≥99% purity.
- USA manufactured.
Fast, Reliable US Shipping
All BioRhex compounds ship from within the United States.
Orders are processed promptly with tracking provided on every shipment. Research timelines should not be delayed by supply logistics.